|
Jul 16
|
SELLAS’ CDK9 inhibitor to advance after “exceeding expectations” in AML
|
|
Jul 15
|
Sellas Life Sciences Meets Primary Endpoints in Mid-Stage SLS009 Trial
|
|
Jul 15
|
SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study
|
|
May 20
|
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase
|
|
May 15
|
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
|
|
Apr 28
|
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference
|
|
Apr 23
|
SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
Jan 2
|
SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET
|
|
Jul 31
|
SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market
|
|
Jun 24
|
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
|
|
Jun 17
|
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
|
|
May 14
|
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 1
|
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
|
|
Apr 29
|
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study
|
|
Mar 28
|
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
|
|
Mar 26
|
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
|
|
Mar 19
|
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
|
|
Mar 19
|
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
|
|
Mar 15
|
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
|
|
Mar 8
|
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
|